Efficacy of intravenous ketamine and intranasal esketamine with dose escalation for Major depression: A systematic review and meta-analysis.
Journal of Affective Disorders July 1, 2024 Ashok Seshadri, Larry J. Prokop, Balwinder Singh 50 citations
Intravenous (IV) racemic ketamine and intranasal (IN) esketamine have demonstrated rapid antidepressant effects in treatment-resistant depression (TRD). This systematic review aims to evaluate the efficacy and safety of ketamine and esketamine at various dosages for depression. We included randomized controlled trials (RCTs) with parallel group dose comparison of ketamine and esketamine for...